Mildreka Hobley Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 915 Selman Rd, Quincy, FL 32351 Phone: 850-321-8981 |
Anthony Ramon Hester, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 15 N Stewart St, Quincy, FL 32351 Phone: 850-875-2180 |
The Neighborhood Ot Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 315 Tillman Rd, Quincy, FL 32352 Phone: 347-749-2167 Fax: 347-710-1292 |
Phaedra Yamean Mashburn-olomo, OTR/L Occupational Therapist Medicare: Medicare Enrolled Practice Location: 315 Tillman Rd, Quincy, FL 32352 Phone: 347-749-2167 |
News Archive
Chemicals that inhibit the development of new blood vessels could prove to be a new way of treating endometriosis, according to research from The Netherlands and the USA presented today (Monday 28 June) at the 20th annual meeting of the European Society of Human Reproduction and Embryology.
Emergent BioSolutions Inc. announced today that its Investigational New Drug (IND) application, to commence a Phase I clinical trial for its anthrax monoclonal antibody therapeutic, has cleared U.S. Food and Drug Administration (FDA) review. The Phase I study will evaluate the safety and pharmacokinetics of the company's fully human monoclonal antibody being developed as a parenteral post-exposure therapy for individuals who have symptoms of anthrax disease. In pre-clinical therapeutic studies, Emergent's monoclonal antibody was found to be effective.
Pioneering research led by Johns Hopkins scientists on the use of partially matched bone marrow transplants to wipe out sickle cell disease has been selected as one of the Top 10 Clinical Research Achievements of 2012 by the Clinical Research Forum.
On March 22, during the 41st Annual Meeting & Exhibition of the American Association for Dental Research (AADR), held in conjunction with the 36th Annual Meeting of the Canadian Association for Dental Research, a symposium titled "Challenges in Salivary Diagnostics" will take place to discuss the issues with saliva collection and storage, proteomic analyses, and the growing interest and availability of commercial tests for salivary biomarkers.
Patients with advanced non-small cell lung cancer can safely take an experimental oral drug intended to protect healthy tissue from the effects of radiation, according to a study led by researchers at the University of Pittsburgh Cancer Institute and published in this month's issue of Human Gene Therapy.
› Verified 3 days ago